RxDoctor Payments DataLook up a doctor →

Sameh Sayfo

Interventional Cardiology · Plano, TXNPI 1144481367

Payments from drug & device makers

$2,503,017in general payments, 2019–2025

Across 1,365 payments — averaging $1833.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$956K
  • Terumo Medical Corporation$455K
  • Penumbra, Inc.$169K
  • Boston Scientific$159K
  • M.a. Med Alliance S.A.$110K
  • Inari Medical, Inc.$110K
  • plus $543K from 50 others
$66in research payments, 2019–2025

Across 1 payment — averaging $65.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$66

What the payments were for

  • Consulting fees$392,88139%
  • Speaking & faculty fees$466,18846%
  • Travel & lodging$110,92611%
  • Food & beverage$39,8454%
  • Education$1540%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,503,017 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$340,028
Medicare patients
633
Services billed
6,604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban254$290,510
Repatha SureclickEvolocumab119$120,448
XareltoRivaroxaban85$119,002
EntrestoSacubitril/Valsartan83$113,737
JardianceEmpagliflozin21$35,807
Praluent PenAlirocumab21$21,034
Ranolazine ErRanolazine147$16,698
BrilintaTicagrelor13$15,164
ClopidogrelClopidogrel Bisulfate416$5,067
Metoprolol Succinate311$3,887
Rosuvastatin Calcium277$3,828
Clonidine20$3,341
Atorvastatin Calcium229$2,588
Nifedipine ErNifedipine44$1,934
Carvedilol169$1,840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$161$119,00285 claims
NovartisEntresto$387$113,73783 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →